What is SION's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.22B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SION?

P/E (TTM) is n/a and 52-week range is $4.01 to $54.97 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SION figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SION?

The company profile lists net income (TTM) near $-98M, EPS (TTM) near $-2.17 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Sionna Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 45.1M shares outstanding, ISIN US8294011080 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Sionna Therapeutics Inc

$SION

Health Care · Biotechnology

Run Scenarios

$4.90

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2025-02-07. The firm is focused on researching and developing novel medicines for cystic fibrosis. The company is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). The company is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. The company is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.

Employees

Website

www.sionnatx.com/

IPO

2025-02-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)